Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 2/20 | 0.45 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.45 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13560161 | 0.93 | EPHX2 (0.41) | GNAI3GNAO1GNAI1EPHX2EPHX1 | |
| SCHEMBL13509613 | 0.88 | GNAI3 (0.40) | GNAI3GNAO1GNAI1EPHX2EPHX1 | |
| SCHEMBL12561511 | 0.88 | POLB (0.51) | GNAI3GNAO1GNAI1EPHX2EPHX1 | |
| SCHEMBL18897210 | 0.88 | GNAI3 (0.40) | GNAI3GNAO1GNAI1EPHX2EPHX1 | |
| SCHEMBL13597080 | 0.86 | GNAI3 (0.53) | GNAI3GNAO1GNAI1CYP1A2POLB | |
| SCHEMBL22562145 | 0.85 | GNAI3 (0.55) | GNAI3GNAO1GNAI1POLBHPGD | |
| SCHEMBL18761634 | 0.85 | GNAI3 (0.55) | GNAI3GNAO1GNAI1POLBHPGD | |
| SCHEMBL1501881 | 0.83 | AKR1C3 (0.43) | GNAI3GNAO1GNAI1EPHX2EPHX1 | |
| SCHEMBL3955878 | 0.83 | EPHX2 (0.42) | GNAI3GNAO1GNAI1EPHX2EPHX1 | |
| SCHEMBL12016032 | 0.83 | GNAI3 (0.45) | GNAI3GNAO1GNAI1POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4393922-A1 | IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| US-20230357177-A1 | SYNTHESIS OF CANNABIDIOL AND ANALOGS THEREOF, AND RELATED COMPOUNDS, FORMULATIONS, AND METHODS OF USE | NALU BIO, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357177-A1 | SYNTHESIS OF CANNABIDIOL AND ANALOGS THEREOF, AND RELATED COMPOUNDS, FORMULATIONS, AND METHODS OF USE | NALU BIO, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11718758-B2 | Aqueous dispersion of colored particles | MITSUBISHI PENCIL COMPANY, LIMITED (JP) | 2023-08-08 | — | — | US | disclosed |
| EP-4194457-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Leadingtac Pharmaceutical Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| WO-2023060369-A1 | NOVEL CARBIMIDATE SUBSTITUTED BICYCLIC COMPOUNDS AND THEIR USE AS BETA-LACTAMASE INHIBITORS | NINGXIA ACADEMY OF AGRICULTURE AND FORESTRY SCIENCES (CN) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023049808-A2 | SMALL MOLECULE INHIBITORS OF TEAD-YAP | THE GENERAL HOSPITAL CORPORATION (US) | 2023-03-30 | — | — | WO | disclosed |
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-05-19 | — | — | US | disclosed |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-7491748-B2 | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| US-20080227834-A1 | DERIVATIVES OF 2-AMINOTHIAZOLES AND 2-AMINO-OXAZOLES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | SANOFI-AVENTIS (FR) | 2008-09-18 | — | — | US | disclosed |
| US-20080227834-A1 | DERIVATIVES OF 2-AMINOTHIAZOLES AND 2-AMINO-OXAZOLES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | SANOFI-AVENTIS (FR) | 2008-09-18 | — | — | US | disclosed |
| US-20080182783-A1 | Growth Hormone Conjugates | NOVO NORDISK A/S (DK) | 2008-07-31 | — | — | US | disclosed |
| WO-2006042848-A9 | GROWTH HORMONE CONJUGATES | NOVO NORDISK AS (DK) | 2007-05-18 | — | — | WO | disclosed |
| US-20070111926-A1 | Conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-17 | — | — | US | disclosed |
| US-20070111926-A1 | Conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-17 | — | — | US | disclosed |
| US-20070105770-A1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-10 | — | — | US | disclosed |
| US-20070105770-A1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-10 | — | — | US | disclosed |
| WO-2007039176-A1 | DERIVATIVES OF 2 -AMINTHIAZOLES AND 2-AMINOOXAZOLES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227834-A1 | DERIVATIVES OF 2-AMINOTHIAZOLES AND 2-AMINO-OXAZOLES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | PPARA, PPARD, PPARG | GNAI3 3289/4885GNAO1 2488/4885GNAI1 3094/4885 |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | SERPINB1, FURIN, HIF1AN | GNAI3 952/4885GNAO1 3623/4885GNAI1 784/4885 |
| US-20230357177-A1 | SYNTHESIS OF CANNABIDIOL AND ANALOGS THEREOF, AND RELATED COMPOUNDS, FORMULATIONS, AND METHODS OF USE | HMBS, CNR2, HPD | GNAI3 1472/4885GNAO1 699/4885GNAI1 1585/4885 |
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | GNAI3 960/4885GNAO1 2127/4885GNAI1 679/4885 |
| US-20070105770-A1 | Transglutaminase mediated conjugation of peptides | TGM2, TGM3, TGM1 | GNAI3 1834/4885GNAO1 3325/4885GNAI1 1692/4885 |
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | GNAI3 325/4885GNAO1 1799/4885GNAI1 247/4885 |
| US-20080182783-A1 | Growth Hormone Conjugates | GHRHR, GHSR, GHITM | GNAI3 2317/4885GNAO1 864/4885GNAI1 2319/4885 |
| US-20070111926-A1 | Conjugation of peptides | DNPEP, ENPEP, ANPEP | GNAI3 4253/4885GNAO1 4716/4885GNAI1 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.